Portfolio

A significant milestone for MindBio is the recent successful completion of a Phase 1 LSD-Microdosing clinical trial involving 80 healthy participants.
MindBio is the only organization in the world to have obtained regulatory approvals for at-home use of LSD in clinical trials. At-home use is crucial for testing and modeling the safety and efficacy of psychedelics within the community, as we strive to have these life-saving medicines approved.
MindBio has two fully funded Phase 2 LSD-Microdosing clinical trials. The first trial focuses on Major Depressive Disorder, where patients meeting DSM-V criteria will receive an open label 8-week LSD microdosing treatment regimen in a naturalistic at-home setting.
This trial will serve as the basis for continuing a much larger Phase 2b triple-dummy, active placebo-controlled trial in depressed patients. The second trial explores the effectiveness of LSD-Microdosing in conjunction with Meaning Centred Psychotherapy in late-stage cancer patients experiencing emotional distress.
The company successfully listed on the Canadian Securities Exchange on May 2023.

The company uses sensor-based technologies to better predict asthma attacks by collecting real-time data from smart watches and smart inhalers. The system can learn from these data using artificial intelligence (AI) to predict risk of future attacks.
Contact us and register your interest to get early access to this opportunity before it goes public.
Company is merging with Life AI.

Multi-modal data, such as behavioural, physiological, and environmental data, can provide valuable insights into depression and anxiety. For example, recent studies have shown that speech features, such as pitch, tone, and rate of speech, can be used to detect depression. Similarly, physiological measures, such as heart rate variability, have been found to be associated with anxiety. MoodAI is a platform that will monitor and measure your Mood and provide digital interventions to support you.
Contact us and register your interest to get early access to this opportunity before it goes public.
Company is merging with Life AI.

Company has developed a proprietary biochemical compound that reduces greenhouse gas emissions from cows by up to 80% at a cost of just $50 per year per cow. The market size is over 12 billion cows.
Contact us and register your interest to get early access to this opportunity before it goes public..
Company is heading towards a listing in North America.

The Company uses Artificial intelligence (AI) approaches that combine autism markers from multiple sources to make sensitive, specific, accessible, and more reliable method for earlier identification of autism. Our team has designed a working solution using AI-based autism assessment process, having tested with over 10,000 individuals with and without autism.
Contact us and register your interest to get early access to this opportunity before it goes public.
Company is merging with Life AI.

Holding Company for medial and health related AI companies and assets.
Contact us and register your interest to get early access to this opportunity before it goes public.
Company is heading towards a listing in North America.